New diabetes shot aims to help when pills and insulin fall short
NCT ID NCT07387003
First seen Feb 04, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study tests a new injectable medicine, GZR101-80, in 345 adults with type 2 diabetes whose blood sugar is not well controlled by current pills or basal insulin. The main goal is to see if the drug lowers blood sugar levels (HbA1c) after 16 weeks. Researchers will also check for side effects and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
Conditions
Explore the condition pages connected to this study.